CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Laurent Levy

Co-Founder & Chief Executive Officer, Nanobiotix

Search every verified Laurent Levy interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Laurent Levy, co-founder and CEO of Nanobiotix, discussed the company's physics-based approach to cancer treatment in a podcast interview. He described the lead asset, a radioenhancer made of hafnium oxide nanoparticles injected into tumors to amplify radiotherapy's effects, which is currently in phase three trials for head and neck cancer. Levy said the primary mechanism involves absorbing energy to kill more cells, and he noted that this process can also expose tumor components to the immune system, potentially affecting distant metastases in some patients. Levy also addressed the company's Nanoprimer platform, which he said could enable a new class of genetic medicines. He emphasized the reproducibility of physics-based approaches, stating that physics is consistent across biological contexts, unlike biological variability. He mentioned that Nanobiotix presents at major oncology and radiation conferences, including ASCO, ESMO, ASTRO, and ESTRO, as well as investor events like Jefferies and JP Morgan.

Recent appearances

Notable quotes

“Des rumeurs, il y en a déjà eu, c'est pas nouveau, il y en aura probablement d'autres. Faut toujours prendre ça avec des pincettes. Est-ce que Johnson va nous racheter un jour ? Peut-être, on verra bien. Pour l'instant, nous, on a notre boulot, on avance et on continue à délivrer de la valeur pour tout le monde.”

“L'idée c'était de se mettre dans une situation où on avait suffisamment de cash pour avancer nos opérations bien évidemment, mais aussi suffisamment de cash pour attendre l'arrivée de milestone payment du contrat que nous avons avec JNG. Et dans les 3 ans qui viennent, comme on l'a annoncé, en dehors même de ce cash qu'on a déjà en banque, on devrait recevoir plus de 200 millions d'euros de milestone si tous les déve”

“Our vision about this approach of using radio enhancer in oncology is if you use a physical mode of action at least from a primary mode of action perspective then it is something you can apply broadly into patient. When you inject a product like a biological product in a patient, you never know if the target is going to be rich, you never know if the target is fully present in the patient and you never know, for exam”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →